Skip to main content
    C

    Crispr Therapeutics AG (CRSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $40.37
    -1.87 (-4.43%)

    Market Cap: $4.10B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Crispr Therapeutics AG (CRSP) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Crispr Therapeutics AG (CRSP) to earn -$4.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $35.49M. Of 23 analysts, 13 rate the stock Buy or Strong Buy, 10 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 9 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 23 ratings average 2.26, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 57% of the ratings.

    RatingAnalystsShare
    Strong Buy417.4%
    Buy939.1%
    Hold1043.5%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    23

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 277.8%.

    Fiscal year ending Dec 31, 2026
    -$4.53
    EPS consensus, revenue $35.49M
    Fiscal year ending Dec 31, 2027
    -$3.69
    EPS consensus, revenue $134.07M
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$4.53-$4.99 to -$4.1219$35.49M$12.33M to $80.89M19
    Dec 31, 2027-$3.69-$5.34 to -$0.4220$134.07M$1.00M to $509.00M18

    Quarterly Estimates

    The EPS consensus rises from -$1.26 for the quarter ending Dec 31, 2026 to -$1.09 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.26-$2.10 to -$0.7922$9.87MN/A21
    Mar 31, 2027-$1.09-$1.33 to -$0.737$11.45M$300000 to $42.55M7

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 13 upward and 16 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202669
    Fiscal year ending Dec 31, 202736
    Quarter ending Mar 31, 202741

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.48.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$4.53-$4.49-$4.45-$4.45-$4.48N/A
    Fiscal year ending Dec 31, 2027-$3.69-$3.75-$3.52-$3.50-$3.51N/A
    Quarter ending Mar 31, 2027-$1.09-$1.09-$0.89-$0.89-$0.89N/A

    Frequently Asked Questions About CRSP

    What is the CRSP stock forecast?

    Consensus analyst estimates put Crispr Therapeutics AG's EPS at -$4.53 for the fiscal year ending Dec 31, 2026, on revenue of $35.49M. The consensus rating from 23 analysts is Buy.

    How do analysts rate CRSP stock?

    Of 23 analysts covering Crispr Therapeutics AG, 4 rate it Strong Buy, 9 Buy, 10 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from CRSP next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.53, with estimates from -$4.99 to -$4.12 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.69, with estimates from -$5.34 to -$0.42 from 20 analysts.

    What revenue do analysts expect from Crispr Therapeutics AG next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $35.49M, with estimates from $12.33M to $80.89M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $134.07M, with estimates from $1.00M to $509.00M.

    How many analysts cover CRSP?

    23 analysts rate Crispr Therapeutics AG stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.